

Katrina G Millard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8257074/publications.pdf>

Version: 2024-02-01

17
papers

7,526
citations

566801

15
h-index

887659

17
g-index

27
all docs

27
docs citations

27
times ranked

13518
citing authors

#	ARTICLE	IF	CITATIONS
1	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> , 2020, 584, 437-442.	13.7	1,742
2	Evolution of antibody immunity to SARS-CoV-2. <i>Nature</i> , 2021, 591, 639-644.	13.7	1,355
3	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. <i>Nature</i> , 2021, 592, 616-622.	13.7	1,232
4	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. <i>Cell</i> , 2020, 182, 828-842.e16.	13.5	724
5	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. <i>Nature</i> , 2021, 595, 426-431.	13.7	610
6	Combination therapy with anti-HIV-1 antibodies maintains viral suppression. <i>Nature</i> , 2018, 561, 479-484.	13.7	392
7	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. <i>Nature</i> , 2021, 600, 517-522.	13.7	239
8	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. <i>Immunity</i> , 2021, 54, 1853-1868.e7.	6.6	230
9	Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. <i>Nature</i> , 2022, 607, 128-134.	13.7	197
10	Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. <i>Nature Medicine</i> , 2018, 24, 1701-1707.	15.2	195
11	Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. <i>Journal of Experimental Medicine</i> , 2018, 215, 2311-2324.	4.2	84
12	Prolonged viral suppression with anti-HIV-1 antibody therapy. <i>Nature</i> , 2022, 606, 368-374.	13.7	75
13	Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. <i>PLoS ONE</i> , 2019, 14, e0219142.	1.1	58
14	Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. <i>Journal of Virology</i> , 2018, 92, .	1.5	39
15	Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial. <i>Lancet Microbe</i> , The, 2022, 3, e203-e214.	3.4	33
16	Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	10
17	Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	5